Research

Hormonal

Tirzepatide may trigger new-onset atrial fibrillation in susceptible individuals through autonomic activation and sinoatrial node effects, despite its overall cardiometabolic benefits.

If you start tirzepatide and feel palpitations, lightheadedness, or a racing heart, seek medical attention promptly. While the drug improves long-term metabolic health, it can increase heart rate and potentially trigger atrial fibrillation in susceptible individuals. Do not ignore new cardiac symptoms.

LimitedQualifiesLOW confidence
This case describes new-onset AF in close temporal association with the initiation of tirzepatide in a woman without structural heart disease or traditional AF risk factors... GLP-1 receptor agonists, including those with dual GIP activity, consistently produce modest increases in resting heart rate, which may reflect autonomic activation and effects on the sinoatrial node.
Akhtar Purvez et al. · Cureus · 2025

Why this rating

Based on a single case report with a 'possible' Naranjo score; lacks controlled trial data for this specific adverse event.

Source

New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report

Akhtar Purvez et al. · Cureus · 2025

DOI 10.7759/cureus.99651

case_report · n=1Cited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →